Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.83
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 […]
